Kornimate/medical-research-clean huggingface dataset:
immediate effect of cervical manual therapy methods in patients with neck pain

Conditions: Neck Pain

Summary: chronic neck pain is an important health problem in modern society and is frequently encountered today. approximately 10% of the adult population experiences neck pain at least once in their lives. anamnesis of the patient with neck pain; it should include the patient's complaints, illness history, family history, social status, work life and leisure activities. the age of the patient, the severity of the symptoms, the mechanism of the injury, the activity history, the duration of the symptoms, the location and limits, the spread of the pain, the relationship of the complaints with the change in position, the restrictions during movement, and the sleeping positions should be taken into account. in addition, past diseases, operations and current diseases, medications used should be recorded. among chronic pains, neck pain ranks second after low back pain. physical stresses in daily living activities, maintaining static posture and sleeping habits, carrying bags and weights in the wrong position, muscle imbalance are important factors in neck pain. although cervical spine involvements have a great effect on neck pain, almost all of them have paravertebral muscle spasm, especially trapezius muscle spasm. physiotherapy applications are widely used in the treatment of chronic neck pain.

therapeutic approaches are frequently used to reduce inflammation and accelerate the healing process. reducing pain in neck diseases, ensuring sufficient length of the muscle, strength balance, improving strength and function, improving postural re-education and cervical movements are the main goals. with the increasing prevalence of neck pain, the search for new treatment methods is increasing. it includes manual therapy, manipulation, acupuncture, and soft tissue therapy for chronic neck pain. neck pain results from deep muscle dysfunctions and altered fascia structures. in this case, it may cause the disruption of the continuous musculofacial corset-like system. in addition, changes in the fascia (increased fascial thickness and disruption of fascial alignment) may affect this system more. myofascial release is one of the soft tissue treatment applications. although there are studies reporting that myofascial release is a method that can achieve positive effects such as reducing pain intensity and improving muscle function, there are few studies on this subject in the literature and sufficient evidence has not been reached.

Eligibility criteria:
inclusion criteria: * neck pain * being between 20-60 years old exclusion criteria: * cardiopulmonary disease * malignancy and pregnancy * operation, injection, etc. for the neck in the last 3 months. those with a history of treatment * spine surgery * psychological discomfort * neurological and orthopedic deficits

Keywords: manuel therapy neck
cognitive priming for stroke tele-rehabilitation

Conditions: Stroke

Summary: the goal of this pilot study is to investigate whether adding cognitive rehabilitation to an existing occupational therapy (ot) stroke telerehabilitation program will improve stroke survivors' functioning. the main question it aims to answer is whether this intervention improves cognition, participation, upper extremity use in real-world activities, and mood/quality of life. participants will be asked to engage in an 8-week stroke tele-rehabilitation program (13 sessions), which includes both cognitive rehabilitation and ot for arm/hand function, and complete assessments before and after the intervention.


Eligibility criteria:
inclusion criteria: * have experienced ischemic or hemorrhagic stroke with resultant paresis of one arm/hand at least 30 days prior * adults ages 21 years or older * are able to speak and read english * have corrected vision to be able to read text on a screen * have a device on which a telerehabilitation visit can be conducted (i.e., phone, tablet, or laptop) and a wi-fi connection or cellular service * able to participate in the study's assessment sessions as per the judgment of the licensed, experienced stroke telerehabilitation occupational therapist. exclusion criteria: * have moderate-severe or severe aphasia. * have impaired decision making capacity as determined by a standard protocol for assessing capacity to provide informed consent.
pharmacokinetics and safety profile of a single dose gzr4 in subjects with renal impairment

Conditions: Diabetes

Summary: this study will be conducted to investigated the effect of decreased kidney function on pk and safety of gzr4 and to guide dosing recommendations in people with kidney impairment.


Eligibility criteria:
inclusion criteria: * male or female, aged 18-75 years (both inclusive) at the time of signing informed consent * meeting the pre-defined glomerular filtration rate (gfr) values exclusion criteria: * known or suspected hypersensitivity to trial product * drugs known to affect creatinine clearance including cimetidine within 14 days or 5 half-lives prior to the day of dosing of gzr4 and during this trial * individuals who routinely undergo dialysis or have a history of renal transplantation, hepatorenal syndrome, or acute kidney injury

Keywords: gzr4 kidney
bioequivalency study of amlodipine tablets under fed conditions

Conditions: Hypertension; Chronic Stable Angina; Vasospastic Angina

Summary: the objective of this study was the bioequivalence of a roxane laboratories' amlodipine besylate tablets, 10 mg, to norvasc® tablets, 10 mg (pfizer) under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening. exclusion criteria: * positive test for hiv, hepatitis b, or hepatitis c. * treatment with known enzyme altering drugs. * history of allergic or adverse response to amlodipine besylate or any comparable or similar product.
fecal microbiota transplantation in patients with irritable bowel syndrome

Conditions: Irritable Bowel Syndrome (IBS)

Summary: the purpose of this study is to investigate the effect of fecal microbiota transplantation (fmt) on the symptoms of irritable bowel syndrome (ibs) patients.


Eligibility criteria:
inclusion criteria for patients 1. signed informed consent 2. fulfilled rome iii diagnostic criteria for ibs, and frequency of ibs pain or discomfort for at least 2 days a week in the last 12 weeks 3. age: 18-65 years exclusion criteria for patients 1. high proportion of butyrate-producing microbiota in fecal samples 2. known organic gastrointestinal disease (e.g. ibd) 3. previous complicated gastrointestinal surgery 4. non-gastrointestinal malignancy 5. dementia, severe depression, major psychiatric disorder, or other incapacity for adequate cooperation 6. females who are pregnant or breast-feeding 7. severe endometriosis 8. antimicrobial treatment 4 weeks prior to first screening visit 9. antimicrobial prophylaxis (eg. acne, urinary tract infection) 10. regular consumption of probiotic products 4 weeks prior to randomization 11. recently (within the last 3 months) diagnosed lactose intolerance 12. celiac disease 13. abuse of alcohol or drugs 14. any clinically significant disease/condition which in the investigator's opinion could interfere with the results of the trial inclusion criteria for donors 1. signed informed consent 2. high-butyrate producing microbiota in fecal samples 3. age: 18-65 years exclusion criteria for donors 1. known organic gastrointestinal disease (e.g. ibd, ibs, chronic diarrhea or constipation) 2. gastrointestinal malignancy or polyposis 3. history of major gastrointestinal surgery (e.g. gastric bypass) 4. eosinophilic disorders of the gastrointestinal tract 5. current communicable disease (e.g. upper respiratory tract infection) 6. known or high risk of infectious diseases such as hiv, hepatitis a, b or c 7. non-gastrointestinal malignancy 8. dementia, severe depression, major psychiatric disorder, or other incapacity for adequate cooperation 9. comorbidities such as metabolic syndrome, autoimmune diseases, allergies 10. chronic pain syndromes (eg. chronic fatigue syndrome, fibromyalgia) 11. severe or morbid obesity 12. use of immunosuppressive or chemotherapy agents 13. antimicrobial treatment or prophylaxis within the last 6 months 14. females who are pregnant or breast-feeding 15. known clinically significant abnormal laboratory values 16. participation in high-risk sexual behaviors 17. abuse of alcohol or drugs 18. tattoo or body piercing within the last 6 months 19. travel to areas with endemic diarrhea during the last 3 months 20. positive stool testing for c. difficile toxin, ova, parasites, giarda antigen, cryptosporidium antigen

Keywords: fecal transplantation microbiota transplantation irritable bowel syndrome ibs
collaborative h1n1 adjuvant treatment (chat) pilot trial

Conditions: H1N1 Influenza

Summary: the chat pilot trial is designed to compare rosuvastatin against placebo in patients with suspected h1n1. the pilot study will assess the feasibility of our clinical protocols, and study procedures.

this trial is a pilot study to assess the feasibility and acceptability of a double blind randomized controlled trial (rct) evaluating the efficacy of rosuvastatin as adjuvant therapy for h1n1 influenza

Eligibility criteria:
inclusion criteria: * critically ill adult patients \> 16 years of age admitted to an adult icu for any reason with suspected, probable or confirmed novel swine origin influenza a/h1n1 infection * requiring mechanical ventilation (invasive or non-invasive) * receiving antiviral therapy (any medication at any dose and for any intended duration) for \< 72 hours * clinicians must have a 'moderate', 'high' or 'moderate to high' index of suspicion for h1n1 exclusion criteria: * age \< 16 years * do not resuscitate or re-intubate order documented on chart or anticipated withdrawal of life support * weight \< 40 kg * unable to receive or unlikely to absorb enteral study drug (e.g. incomplete or complete bowel obstruction, intestinal ischemia, infarction, short bowel syndrome) * rosuvastatin specific exclusions: 1. already receiving a statin (atorvastatin, lovastatin, simvastatin, pravastatin, rosuvastatin) 2. allergy or intolerance to statins 3. receiving niacin, fenofibrate, cyclosporine, gemfibrozil, lopinavir, ritonavir or planned use of oral contraceptives or estrogen therapy during the icu stay 4. ck exceeds 10 times uln or alt exceeds 8 times the uln * severe chronic liver disease (child-pugh score 11-15) (see appendix 6) * previous enrolment in this trial * pregnancy or breast feeding * at the time of enrolment, patients must not have received \>72 hours of antiviral therapy

Keywords: h1n1 rosuvastatin
assessment of peripheral perfusion in the critically ill patient

Conditions: Peripheral Perfusion

Summary: the purpose of this study is to evaluate ppi as a surrogate for clinical signs of peripheral perfusion in patients in septic shock and after cardiac surgery.

the aim of this study is to validate ppi as a continuous, objective measurement of peripheral perfusion indicated by clinical sings of tissue perfusion in patients with septic shock. furthermore, ppi shall be compared to the perfusion of solid organs evaluated by ultrasound of liver, kidney and gut. in a group of healthy volunteers the investigators will determine normal values in ambient temperature and after cooling of an extremity. another group of patients after cardiac surgery, where usually a poor tissue perfusion without metabolic failure is present will serve as another "control" population in their post-surgery stabilization period. the values from healthy volunteers and cardiac surgery patients will be compared to those of patients in septic shock.

Eligibility criteria:
septic patient: inclusion criteria: * icu admission with septic shock defined as: * documented infection (suspected or confirmed) and * systemic mean blood pressure \<65mmhg requiring any dose of vasopressor despite adequate fluid resuscitation (min. 20ml/kg crystalloids) and * lactate \>2mmol/l * deferred consent by a relative with following informed consent by patient as documented by signatures (appendix informed consent form) exclusion criteria: * age \ 80 years * present or suspected myocardial ischemia * acute pulmonary embolism * known liver disease - child-pugh -class b or c * known chronic renal failure * known peripheral artery disease patient after cardiac surgery: inclusion criteria: * icu admission after coronary artery bypass grafting or valve surgery with cardiopulmonary bypass * general consent with admission at the university hospital exclusion criteria: * age \ 80 years * known peripheral artery disease * no or only low dose of vasopressors (\<300µg/h) at icu admission * present or suspected myocardial ischemia * acute pulmonary embolism * known liver disease - child-pugh -class b or c * known chronic renal failure healthy volunteers: inclusion criteria: - informed consent as documented by signature (appendix informed consent form) exclusion criteria: * age \ 80 years * known peripheral artery disease

Keywords: critically ill patients septic shock peripheral perfusion index capillary refill time mottling score microcirculation
a clinical study of shr-a1811 combined with chemotherapy for platinum sensitive recurrent ovarian cancer

Conditions: Ovarian Cancer

Summary: the objective is to evaluate the tolerance, safety, pharmacokinetic characteristics and immunogenicity of shr-a1811 combined with carboplatin and bevacizumab in the treatment of platinum sensitive recurrent epithelial ovarian cancer, and to determine the rp2d of the combination, and preliminarily to evaluate the effectiveness of shr-a1811 combined regimen in the treatment of platinum sensitive recurrent epithelial ovarian cancer.


Eligibility criteria:
inclusion criteria: 1. voluntarily join this study, sign the informed consent form, have good compliance, and can cooperate with the follow-up. 2. sufficient fresh or archived tumor tissue specimens can be provided for testing by the third-party central laboratory designated by the sponsor. 3. at least one measurable lesion conforming to recist v1.1. 4. ecog ps score: 0-1. 5. expected survival ≥ 12 weeks. 6. female subjects with fertility must agree to comply with the contraceptive requirements from signing the informed consent form to 7 months after the last administration of the trial drug. exclusion criteria: 1. with untreated or active central nervous system (cns) tumor metastasis. subjects with a history of meningeal metastasis or current meningeal metastasis. 2. pleural effusion, pericardial effusion or peritoneal effusion with clinical symptoms, which cannot be well controlled. 3. previous interstitial pneumonia or interstitial lung disease, non infectious pneumonia requiring steroid treatment. 4. with hypertension and cannot be well controlled by antihypertensive drug treatment. 5. accompanied by poorly controlled or serious cardiovascular diseases. 6. subjects with serious infection within 1 month before the first medication. 7. have a history of immune deficiency, including hiv test positive, other acquired or congenital immune deficiency diseases, or a history of organ transplantation. 8. there are any other factors that may affect the results of the study or cause the forced termination of the study, such as alcohol abuse, drug abuse, criminal detention, and other serious diseases (including mental illness) that need combined treatment.
elimination of odor and treatment of malodorous recalcitrant wounds by using supraz and prp-fg versus standard of care

Conditions: Wounds and Injuries

Summary: the aim of this study is to eliminate the malodorous of chronic wound and increase the chance of the healing of recalcitrant wounds by using the repairing gel (supraz gel) which has the approved components in wound healing and platelet-rich plasma-fibrin glue.

the current study assesses the effects of platelet-rich plasma-fibrin glue (prp-fg) along with the use of the repairing gel which has the approved components on wound healing in patients with chronic wounds and to eliminate the malodorous of chronic wound. this randomized controlled trial is performed on patients with chronic wounds. patients will be treated with repairing gel (supraz gel) plus prp-fg dressing (intervention group) or only supraz gel (intervention group) or only prp-fg dressing (intervention group) every 48 hours for 8 weeks versus standard of care of treatment (control group: irrigation of wound by normal saline 0.9%).

Eligibility criteria:
inclusion criteria: * having a single wound on the body that has been at least 3 months old and has not been repaired by wound irrigation with normal saline and changing the dressing * having a body mass index of 18-35 * sign the informed consent by the patient exclusion criteria: * having concurrent diseases that may cause problems in wound healing, such as cancers, vasculitis, kidney and liver failure, and heart failure * taking certain drugs that may interfere with wound healing, such as corticosteroids, immunosuppressive agents, and cytotoxic agents

Keywords: platelet-rich plasma-fibrin glue repairing gel chronic wounds malodorous recalcitrant
a phase i study of osilodrostat (lci699) in healthy volunteers and subjects with impaired renal function

Conditions: Renal Impairment

Summary: to characterize the pharmacokinetics of lci699 following a single oral dose in adult subjects with various degrees of impaired renal function.


Eligibility criteria:
inclusion criteria: * weight must be ≥50 kg and bmi must be between 18-35 kg/m2 * subjects must have stable renal disease without evidence of progressive decline in renal function (stable renal disease is defined as no significant change, such as, stable egfr \<90 ml/min, for 12 weeks prior to study entry) other than renal impairment, subjects must be stable and appropriately managed relative to chronic diseases (such as diabetes and hypertension) exclusion criteria: * history of any surgical or medical condition other than renal impairment which might significantly alter the absorption, distribution, metabolism or excretion of drugs. * subjects with ongoing alcohol or drug abuse within 1 month prior to dosing or evidence of such abuse as indicated by the laboratory assays conducted during the screening or baseline evaluations. * subjects with screening 12-lead ecg qtcf of \> 450 msec for males or \> 460 msec for female * history of diabetes mellitus (type 1 or 2) or blood glucose of \>125 mg/dl at screening * subjects with potassium levels greater than the upper limit of normal (\>uln) other protocol defined inclusion/exclusion may apply.

Keywords: renal impairment, osilodrostat, lci699
tomographic analysis of anterior, posterior, total corneal refractive power changes after laser-assisted keratotomy

Conditions: Corneal Astigmatism

Summary: to analyze the effect of femtolaser-assisted keratotomy on corneal astigmatism (anterior, posterior and total corneal refractive power) measured by scheimpflug tomography after laser lens surgery.

this study investigated patients' eyes with low to moderate total corneal refractive power determined with scheimpflug tomography (pentacam hr) after penetrating femtosecond laser-assisted keratotomy (pflak) and laser lens surgery. the anterior corneal astigmatism, posterior corneal astigmatism and total corneal refractive power were determined before, 1 month and 3 months after lens surgery. vector analysis according to the alpins' method was used to calculate surgically induced astigmatism (sia).

Eligibility criteria:
inclusion criteria: - patients who received penetrating femtosecond laser-assisted lens surgery with low to moderate corneal astigmatism exclusion criteria: * eyes with irregular corneal astigmatism such as keratoconus, previous corneal surgery, acute or chronic ophthalmic diseases of the anterior segment and intraoperative complications were not included in this study.

Keywords: laser-assisted keratotomy anterior astigmatism posterior astigmatism total corneal refractive power nomogram
a pharamcogenomic study for isoniazid according to nat2 polymorphism status

Conditions: Tuberculosis; Drug-Induced Liver Injury; Adverse Drug Event

Summary: a clinical trial to investigate the appropriate dose of isoniazid according to nat2 polymorphism status in korean subjects


Eligibility criteria:
inclusion criteria: * agreement with written informed consent * adult healthy male or female subject age 20 to 45 exclusion criteria: * clinically significant, active gastrointestinal system, cardiovascular system, pulmonary system, renal system, endocrine system, blood system, digestive system, central nervous system, mental disease or malignancy * medication with any drug which may affect the pharmacokinetics of isoniazid within 14 days * previously donate whole blood within 30 days or previously participated in other trial within 60 days * subject with known for hypersensitivity reactions to isoniazid * subject who can not perform contraception during study periods * female woman who are pregnant or are breast feeding * an impossible one who participates in clinical trial by investigator's decision including laboratory test result
effect of vitamin d supplementation on health of low birth weight infants

Conditions: Vitamin D Deficiency

Summary: the purpose of this study is to determine whether a weekly supplement of vitamin d to low birth weight term infants will reduce their mortality and hospital admissions and improve their immunity.

we are conducting a randomised controlled trial of weekly oral vitamin d supplements to low birth weight (\< 2.5 kg) term infants born in a large government hospital catering to a low-middle income population in delhi. mothers and infants are recruited at delivery and given weekly vitamin d supplements or placebo until 6 months of age. data on infant morbidity, sun exposure and diet, with particular emphasis on breast milk and other milk intake, is collected by fieldworkers visiting the homes each fortnight. mothers are encouraged to bring their infants to the hospital in case of any illness and at these visits the infant is seen by the project doctor who treats the infant and records additional morbidity data. at 6 months blood samples are being collected from a 20% random subsample of infants for measurement of 25ohd and indicators of immune activation. the primary outcome is mortality or incidence of any illness requiring admission to hospital.

Eligibility criteria:
inclusion criteria: * born at term, as determined from last menstrual period * weighing \< 2.5 kg * resident within 12 km of the hospital and expected to continue living in the area for the following 6 months * with no severe congenital abnormalities * no morbidity severe enough to be expected to result in death before 7 days due to severe respiratory distress, shock, pulmonary sepsis, etc. * parental informed consent

Keywords: vitamin d3 morbidity mortality low birth weight supplementation th1 th2 crp neopterin immune response
postoperative canadian oral anticoagulation self-management (post-coags) trial

Conditions: Cardiovascular Abnormalities

Summary: this study will measure the efficacy and safety of an early postoperative anticoagulation self-management program, using the coaguchek s device, in patients undergoing mechanical valve replacements. patients will be randomized into a study group (self-management) or a control group (physician management).


Eligibility criteria:
inclusion criteria: * adult patients, 18-70 years of age; * recipient of a mechanical heart valve (aortic and/or mitral), +/- cabg, +/- postoperative atrial fibrillation. exclusion criteria: * recipient of a bioprosthetic valve; * post-operative thrombotic events; * pre-operative utilization of oral anticoagulation.